Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 366 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Second-line Treatment Clear all
Completed Phase 2 Interventional Results available

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

NCT01111604
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Ramucirumab, Icrucumab, mFOLFOX-6
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbia, South Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 11, 2026, 2:36 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

NCT05403385
View directory record Official record
Conditions
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Interventions
inupadenant, Placebo, Carboplatin, Pemetrexed
Drug
Lead sponsor
iTeos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Fayetteville, Arkansas • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 11, 2026, 2:36 AM EDT
Not listed Phase 2 Interventional

T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy

NCT00022243
View directory record Official record
Conditions
Lung Cancer
Interventions
batabulin sodium
Drug
Lead sponsor
Tularik
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
San Francisco, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 11, 2026, 2:36 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

NCT01933932
View directory record Official record
Conditions
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions
Selumetinib, Docetaxel, Placebo, Pegylated G-CSF
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
17
States / cities
Aurora, Colorado • Pembroke Pines, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 11, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

NCT00997334
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Erlotinib
Drug
Lead sponsor
David M. Jackman, MD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 11, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

NCT00940316
View directory record Official record
Conditions
Colorectal Cancer
Interventions
panitumumab, erlotinib hydrochloride, irinotecan hydrochloride
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
10
States / cities
Arlington Heights, Illinois • Chicago, Illinois • Joliet, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 11, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC

NCT00252382
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
SNS-595 Injection
Drug
Lead sponsor
Sunesis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Scottsdale, Arizona • Louisville, Kentucky • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Sep 11, 2026, 2:36 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)

NCT01652482
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-fluorouracil, Cetuximab, Irinotecan, Leucovorin, MEHD7945A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
19
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 11, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Tesetaxel in Metastatic Melanoma

NCT01064713
View directory record Official record
Conditions
Advanced Melanoma, Cancer
Interventions
Tesetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 11, 2026, 2:36 AM EDT
Terminated Phase 2 Interventional

Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma

NCT00735332
View directory record Official record
Conditions
Melanoma
Interventions
TLN-232
Drug
Lead sponsor
Thallion Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2010 · Synced Sep 11, 2026, 2:36 AM EDT
Completed Phase 3 Interventional

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00005093
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine hydrochloride, tacedinaline
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
9
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 11, 2026, 2:36 AM EDT
Terminated Phase 3 Interventional

Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors

NCT00072215
View directory record Official record
Conditions
Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions
cisplatin, ifosfamide, paclitaxel, vinblastine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
78
States / cities
Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2016 · Synced Sep 11, 2026, 2:36 AM EDT
Completed Phase 3 Interventional Results available

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC

NCT03665441
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
eryaspase, Gemcitabine plus Abraxane, Irinotecan plus 5-FU plus leucovorin
Drug
Lead sponsor
ERYtech Pharma
Industry
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Scottsdale, Arizona • Fullerton, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 11, 2026, 2:36 AM EDT
Terminated Phase 2 Interventional Results available

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

NCT04363801
View directory record Official record
Conditions
Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
Interventions
DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 twice daily (BID), Leucovorin Calcium, Fluorouracil
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 11, 2026, 2:36 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

NCT06105632
View directory record Official record
Conditions
Advanced or Metastatic Breast Cancer
Interventions
PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Irvine, California • Los Angeles, California • Newport Beach, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 11, 2026, 2:36 AM EDT
Completed Phase 2 Interventional

Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00114192
View directory record Official record
Conditions
Lung Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2010 · Synced Sep 11, 2026, 2:36 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

NCT07188558
View directory record Official record
Conditions
Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed
Interventions
rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel
Biological
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
36
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 11, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

NCT00903175
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
everolimus, sunitinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 11, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

NCT03483103
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Interventions
lisocabtagene maraleucel
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
59
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 11, 2026, 2:36 AM EDT
Completed Phase 2 Interventional Results available

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

NCT00696072
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Dasatinib, Letrozole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
27
States / cities
Sedona, Arizona • Tucson, Arizona • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 11, 2026, 2:36 AM EDT
Not listed Phase 2 Interventional

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

NCT01095120
View directory record Official record
Conditions
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction
Interventions
Tesetaxel
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 11, 2026, 2:36 AM EDT
Not listed Phase 2 Interventional

Temsirolimus as Second-line Therapy in HCC

NCT01567930
View directory record Official record
Conditions
Unresectable or Metastatic Hepatocellular Carcinoma
Interventions
Temsirolimus
Drug
Lead sponsor
University of Tennessee Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 11, 2026, 2:36 AM EDT
Not yet recruiting Phase 4 Interventional

Second Line Endovascular Treatment in Acute DVT

NCT06486181
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Thrombolysis/Thrombectomy
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 11, 2026, 2:36 AM EDT
Terminated Phase 2 Interventional

Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

NCT01402401
View directory record Official record
Conditions
Advanced Gastric Cancer
Interventions
AUY922, Trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Los Angeles, California • Lake Success, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 11, 2026, 2:36 AM EDT